Rigel Pharmaceuticals, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.30 | -$0.27 | -$0.29 |
Q2 2024 | 1 | -$0.30 | -$0.28 | -$0.29 |
Q3 2024 | 1 | $0.06 | $0.06 | $0.06 |
Q4 2024 | 4 | $0.13 | $0.57 | $0.30 |
Q1 2025 | 1 | $0.16 | $0.18 | $0.17 |
Q2 2025 | 1 | $0.25 | $0.28 | $0.27 |
Q3 2025 | 1 | $0.19 | $0.21 | $0.20 |
Q4 2025 | 1 | $0.15 | $0.17 | $0.16 |
Rigel Pharmaceuticals, Inc. Earnings Date And Information
Rigel Pharmaceuticals, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $0.7 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.64. The company had revenue of 55.31 M for the quarter and had revenue of 116.88 M for the year. Rigel Pharmaceuticals, Inc. has generated $-1 earnings per share over the last year ($-1.44 diluted earnings per share) and currently has a price-to-earnings ratio of 103.12. Rigel Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based on prior year's report dates.
Rigel Pharmaceuticals, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/07/2024 | Q3 2024 | $0.06 | $0.71 | 0.65 | $41.94 M | $55.31 M |
08/06/2024 | Q2 2024 | -$0.37 | -$0.06 | 0.31 | $33.42 M | $36.84 M |
05/07/2024 | Q1 2024 | -$0.30 | -$0.47 | -0.17 | $29.53 M | |
03/05/2024 | Q4 2023 | $0.00 | $0.04 | 0.04 | $35.79 M | |
11/07/2023 | Q3 2023 | -$0.07 | -$0.33 | -0.26 | $27.20 M | $28.13 M |
08/01/2023 | Q2 2023 | -$0.08 | -$0.38 | -0.3 | $25.70 M | $26.89 M |
05/02/2023 | Q1 2023 | -$0.09 | -$0.78 | -0.69 | $26.07 M | |
03/07/2023 | Q4 2022 | -$0.07 | $0.08 | 0.15 | $51.28 M | |
11/03/2022 | Q3 2022 | -$0.13 | -$1.10 | -0.97 | $22.61 M | $22.41 M |
08/02/2022 | Q2 2022 | -$0.12 | -$0.78 | -0.66 | $23.65 M | $29.82 M |
05/03/2022 | Q1 2022 | -$0.12 | -$1.60 | -1.48 | $16.74 M | |
03/01/2022 | Q4 2021 | -$0.13 | -$1.32 | -1.19 | $20.41 M | |
11/02/2021 | Q3 2021 | -$0.10 | -$1.23 | -1.13 | $23.56 M | $21.54 M |
08/03/2021 | Q2 2021 | -$0.11 | -$0.81 | -0.7 | $20.37 M | $26.27 M |
05/05/2021 | Q1 2021 | $0.00 | $2.33 | 2.33 | $81.02 M | |
03/02/2021 | Q4 2020 | -$0.10 | -$1.14 | -1.04 | $18.45 M | |
11/05/2020 | Q3 2020 | -$0.12 | -$0.84 | -0.72 | $17.24 M | $18.39 M |
08/04/2020 | Q2 2020 | -$0.13 | -$1.04 | -0.91 | $13.75 M | $16.02 M |
05/05/2020 | Q1 2020 | $0.13 | $1.26 | 1.13 | $55.76 M | |
02/27/2020 | Q4 2019 | -$0.11 | -$1.03 | -0.92 | $15.40 M |
Rigel Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Rigel Pharmaceuticals, Inc.'s earnings date?
Rigel Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates.
-
Did Rigel Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Rigel Pharmaceuticals, Inc. (:RIGL) reported $0.7 earnings per share (EPS) to beat the analysts' consensus estimate of $0.06 by $0.64.
-
How can I listen to Rigel Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Rigel Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Rigel Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Rigel Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Rigel Pharmaceuticals, Inc. generate each year?
Rigel Pharmaceuticals, Inc. (:RIGL) has a recorded annual revenue of $116.88 M.
-
How much profit does Rigel Pharmaceuticals, Inc. generate each year?
Rigel Pharmaceuticals, Inc. (:RIGL) has a recorded net income of $116.88 M. Rigel Pharmaceuticals, Inc. has generated $-1.44 earnings per share over the last four quarters.
-
What is Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio?
Rigel Pharmaceuticals, Inc. (:RIGL) has a price-to-earnings ratio of 103.12 and price/earnings-to-growth ratio is 0.18.